Planchard D, Smit E, Groen H, et al. Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC). ESMO 2017 Congress, abstract LBA51
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker